Conference Call and Webcast on Tuesday, August 12, 2014 at 4:30 p.m.
ANN ARBOR, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (NASDAQ: ESPR) a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol
(LDL-cholesterol) lowering therapies for the treatment of
hypercholesterolemia and other cardiometabolic risk markers, today
announced it will host a conference call and webcast to report
operational and financial results from the second quarter 2014. The
webcast will take place on Tuesday, August 12, 2014 at 4:30 p.m. Eastern
The call can be accessed by dialing (877) 831-3840 (domestic) or (253)
237-1184 (international) five minutes prior to the start of the call and
providing access code 76041931. A live, listen-only webcast of the
conference call can be accessed on the investor relations section of the
Esperion website at www.esperion.com.
A webcast replay of the call will be available approximately two hours
after completion of the call and will be archived on the company's
website for two weeks.
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients with
cardiometabolic diseases. The Esperion team leverages its understanding
of, and experience with, key biological pathways to discover and develop
innovative therapies for the treatment of patients with
hypercholesterolemia who have uncontrolled cholesterol levels despite
the use of currently available therapies. Esperion has assembled a
portfolio of programs including one product candidate in late-stage
clinical evaluation and two pre-clinical product candidates.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on developing and commercializing first-in-class, oral,
LDL-cholesterol lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower LDL-cholesterol
levels and avoid the side effects associated with therapies currently
available for lowering LDL-cholesterol. ETC-1002 is being developed
primarily for patients with hypercholesterolemia and a history of statin
intolerance. Phase 2b clinical trials for ETC-1002 are currently
underway and build upon the successful and comprehensive Phase 1 and
Phase 2a programs. For more information, please visit www.esperion.com
and follow us on Twitter at https://twitter.com/EsperionInc.
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media